Skip to main content
PMC home page
Journal of Clinical Laboratory Analysis logoLink to Journal of Clinical Laboratory Analysis
. 2009 Jul 21;23(4):197–201. doi: 10.1002/jcla.20331

Expression of CD4+CD25highCD127low/− regulatory T cells in transitional cell carcinoma patients and its significance

Xi Zhu 1, Lin‐Lin Ma 1, Tian Ye 1,✉
PMCID: PMC6649147  PMID: 19623656

Abstract

To evaluate the expressions of CD4+CD25highCD127low/− regulatory T cells (Tregs) in peripheral blood from patients with transitional cell carcinoma (TCC) in urinary system, we investigated the proportion of Treg population in CD4+ T from 93 patients with TCC, 38 with benign urinary diseases, and 37 healthy subjects by using flow cytometric analysis and analyzing different clinicopathologic characteristics and the changes before and after operation. We found that the proportion of Treg in peripheral blood from patients with TCC was significantly increased as compared with the othertwo groups. There was a strong correlation between the proportion of Treg and tumor recurrence, quantity, lymph node metastasis (P<0.01), as well as pathological stage; no correlation was found between the proportion of Treg and clinical TNM stage (P>0.05). The proportion of Treg was also different before and after operation (P<0.05). This suggest that CD4+CD25+CD127low/− regulatory T cells may be responsible for immune suppression in TCC patients. The resection of tumor can decrease the proportion of Treg in peripheral blood. J. Clin. Lab. Anal. 23:197–201, 2009. © 2009 Wiley‐Liss, Inc.

Keywords: transitional cell carcinoma, regulatory T cells, urologic diseases, cellular immunity

REFERENCES

  • 1. Dercamp C, Chemin K, Caux C, Trinchieri G, Vicari AP. Distinct and overlapping roles of interleukin‐10 and CD25+ regulatory T cells in the inhibition of antitumor CD8 T‐cell responses. Cancer Res 2005;65:8479–8486. [DOI] [PubMed] [Google Scholar]
  • 2. Ghiringhelli F, Menard C, Terme M, et al. CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor beta‐dependent manner. J Exp Med 2005;202:1075–1085. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3. Banham AH. Cell‐surface IL‐7 receptor expression facilitates the purification of FOXP3(+) regulatory T cells. Trends Immunol 2006;27:541–544. [DOI] [PubMed] [Google Scholar]
  • 4. Hartigan‐O'Connor DJ, Poon C, Sinclair E, McCune JM. Human CD4+ regulatory T cells express lower levels of the IL‐7 receptor alpha chain (CD127), allowing consistent identification and sorting of live cells. J Immunol Methods 2007;319:41–52. [DOI] [PubMed] [Google Scholar]
  • 5. Li‐Song S, Jian W, Ding‐Feng S, et al. CD4+CD25+CD127low/− regulatory T cells express Foxp3 and suppress effector T cell proliferation and contribute to gastric cancers progression. Clin Immunol 2009;131:109–118. [DOI] [PubMed] [Google Scholar]
  • 6. Sasaki A, Tanaka F, Mimori K, et al. Prognostic value of tumor‐infiltrating FOXp3+ regulatory T cells in patients with hepatocellular carcinoma. Eur J Surg Oncol 2008;34:173–179. [DOI] [PubMed] [Google Scholar]
  • 7. Mittal S, Marshall NA, Duncan L, et al. Local and systemic induction of CD4+CD25+ regulatory T‐cell population by non‐Hodgkin lymphoma. Blood 2008;111:5359–5370. [DOI] [PubMed] [Google Scholar]
  • 8. Gacci M, Serni S, Lapini A, et al. Regulatory T cells expression in peripheral blood and tumour infiltrate of patients with renal cell carcinoma: Correlation with prognostic factors. Eur Urol Suppl 2008;7:99. [Google Scholar]
  • 9. Yokokawa J, Cereda V, Remondo C, et al. Enhanced functionality of CD4+CD25highFoxP3+ regulatory T cells in the peripheral blood of patients with prostate cancer. Clin Cancer Res 2008;14:1032–1040. [DOI] [PubMed] [Google Scholar]
  • 10. Loskog A, Ninalga C, Paul‐Wetterberg G, et al. Human bladder carcinoma is dominated by T‐regulatory cells and Th1 inhibitory cytokines. J Urol 2007;177:353–358. [DOI] [PubMed] [Google Scholar]
  • 11. Jarnicki AG, Lysaght J, Todryk S, et al. Suppression of antitumor immunity by IL‐10 and TGF‐beta‐producing T cells infiltrating the growing tumor: Influence of tumor environment on the induction of CD4+ and CD8+ regulatory T cell. J Immunol 2006;177:896–904. [DOI] [PubMed] [Google Scholar]
  • 12. Demelza JN, Jing XL, Manfred WB. Intra‐tumoural regulatory T cells: A potential new target in cancer immunotherapy. Biochem Biophys Res Commun 2006;343:684–691. [DOI] [PubMed] [Google Scholar]
  • 13. Tyler JC. Regulatory T cells and treatment of cancer. Curr Opin Immunol 2008;20:241–246. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of Clinical Laboratory Analysis are provided here courtesy of Wiley

RESOURCES